Clinical trials: Risperidone, completed
Child Development Disorders, Pervasive
Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)
The purpose of this study is to determine if the known differences in genes influence drug metabolizing enzymes and receptors that are involved in risperidone drug action.
- Trial name
- NCT00166595
- Testing
- Risperidone
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Mania, Schizophrenia
Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect
With this observational study we want to examine if the intensity of agitation, the intensity of psychotic symptoms and the presence of sleeping disorder predict the success of the treatment with a atypical antipsychotic after 12…
- Trial name
- UPTAQE (NCT00534222)
- Where
- 6 sites in Netherlands
- Volunteers
- 387 people
- Sponsor
- AstraZeneca
Schizophrenia, Psychotic Disorders
Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia
The purpose of this study is to compare the effectiveness of two antipsychotic medications, Risperdal® Consta® versus Abilify®, over a 2-year treatment period in the long-term maintenance of patients with schizophrenia.
- Trial name
- NCT00299702
- Testing
- Abilify, Risperidal Consta
- Volunteers
- 355 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Psychotic Disorders
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
The purpose of the study is to compare effectiveness of paliperidone palmitate (PP: paliperidone palmitate once-monthly and 3-month injections) versus oral antipsychotic (OAP [that is oral paliperidone extended release {ER}, oral…
- Trial name
- DREaM (NCT02431702)
- Testing
- Aripiprazole, Haloperidol, Olanzapine
- Where
- 38 sites in United States, Brazil and 1 more
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Janssen Scientific Affairs, LLC
Schizoaffective Disorder, Schizophrenia
Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
In the proposed study 450 veterans with a primary diagnosis of schizophrenia who had at least one psychiatric hospitalization for schizophrenia in the previous 2 years would be randomly assigned at 16 VA medical centers to…
- Trial name
- NCT00132314
- Testing
- IM risperidone, oral antipsychotic medication
- Where
- 19 sites in United States
- Volunteers
- 382 people
- Sponsor
- US Department of Veterans Affairs
Healthy
Risperidone Tablets, 1 mg Bioequivalence Study of Dr.Reddy's Under Fed Condition
A Single-dose, Randomized, two-Period, Cross over Study
- Trial name
- NCT01064271
- Testing
- Risperidone
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Schizophrenia
Risperidone Augmentation in Patients With Schizophrenia
We propose a double-blind, placebo-controlled trial to study the effectiveness and tolerability of adding risperidone to stable yet only partially remitted patients with schizophrenia maintained on clozapine.
- Trial name
- NCT00289861
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Metabolic Syndrome X
An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics
The purpose of the study is to find and follow-up the metabolic syndrome parameters on patients administering atypical antipsychotics.
- Trial name
- MESSAGE (NCT00448630)
- Testing
- No intervention
- Where
- 47 sites in Turkey (Türkiye)
- Volunteers
- 328 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Cannabis Abuse
Clozapine for Cannabis Use in Schizophrenia
Many individuals with schizophrenia also suffer from marijuana addiction that worsens their problems related to schizophrenia. Most of the medications prescribed for schizophrenia have no effect on reducing marijuana use.
- Conditions
- Schizophrenia, Cannabis Abuse, Cannabis Dependence, Dual Diagnosis
- Trial name
- CLOCS (NCT01639872)
- Testing
- Clozapine, Risperidone
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Healthy
Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fasting Conditions
The purpose of this study is to determine the pharmacokinetics and bioequivalence of Risperidone formulations after administration of single doses to normal, healthy subjects under fasted conditions.
- Trial name
- NCT01222975
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Ranbaxy Laboratories Limited
Schizophrenia
The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
A clinical study to compare the safety and effectiveness of two different dose ranges of risperidone solution in the treatment of adolescents with a diagnosis of schizophrenia.
- Trial name
- NCT00034749
- Testing
- Risperidone
- Volunteers
- 279 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Schizophrenia, Schizoaffective Disorder
POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia
This Phase I/IIa Proof-of-Concept (PoC) trial is designed to assess the effect of adding a single and repeated low dose (15mg/d) of pipamperone (PIP) for 6 weeks to stable treatment with an effective dose of risperidone (RIS) or…
- Trial name
- NCT01450514
- Testing
- Pipamperone
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- PharmaNeuroBoost N.V.
Schizophrenia
An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to evaluate the efficacy and safety of long acting injectable (LAI) risperidone and oral risperidone treatment on participants with schizophrenia (psychiatric disorder with symptoms of emotional…
- Trial name
- NCT00992407
- Testing
- Risperidone long acting injectables, Risperidone tablets
- Where
- South Korea
- Volunteers
- 75 people
- Sponsor
- Janssen Korea, Ltd., Korea
Autism Spectrum Disorder
Electrical Brain Stimulation and Pharmacological Treatments in Autism Spectrum Disorder
This project aims to comparing the effectiveness of transcranial direct current stimulation with common pharmacological treatments on behavioral problems and cognitive deficits of children with autism spectrum disorder
- Trial name
- NCT05491720
- Testing
- RisperiDONE 1 MG/ML, transcranial direct current stimulation
- Where
- Iran
- Volunteers
- 45 people
- Sponsor
- The National Brain Mapping Laboratory (NBML)
Sleep Problems
Understanding Sleep Problems in Children With Autism Spectrum Disorder
The investigators will examine whether sleep problems in children with autism spectrum disorder (ASD) are related to alterations in the production of melatonin (MT), a hormone that plays an important role in regulating sleep-wake…
- Trial name
- REST (NCT00691080)
- Where
- 3 sites in United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Schizophrenia, Psychotic Disorders
Effect of Curcumin Add-On Therapy on Quality of Life and IL-1β Levels in Patients With Schizophrenia
This study aims to evaluate the effect of curcumin extract as an adjuvant therapy on quality of life and inflammatory markers in patients with schizophrenia receiving risperidone.
- Trial name
- CUR-SCZ (NCT07523256)
- Testing
- Curcumin, Risperidone 4mg/day
- Where
- Indonesia
- Volunteers
- 44 people
- Sponsor
- Rinvil Renaldi
Schizophrenia
Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)
The purpose of this study is to examine treatment practices of adult schizophrenia patients by their own doctors, and to assess patient outcomes when treated with long-acting risperidone injection over a two-year period of…
- Trial name
- SOURCE (NCT00246194)
- Testing
- risperidone (RISPERDAL CONSTA)
- Where
- United States
- Volunteers
- 532 people
- Sponsor
- Janssen, LP
Schizophrenia, Psychotic Disorders
Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis
The purpose of this research study is to see how well patients in an early phase of their illness respond to treatment and whether this depends on how well they functioned socially, academically and vocationally before becoming…
- Conditions
- Schizophrenia, Psychotic Disorders, Schizoaffective Disorder
- Trial name
- NCT00369239
- Testing
- risperidone long acting injectable
- Volunteers
- 303 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia
Study Evaluating Vabicaserin in Subjects With Schizophrenia
The primary purpose of this protocol is to establish the efficacy, safety, and tolerability of vabicaserin (SCA-136) using a once a day capsule in subjects with acute exacerbations of schizophrenia.
- Trial name
- NCT00563706
- Testing
- vabicaserin, risperidone
- Where
- 33 sites in United States, Canada
- Volunteers
- 199 people
- Sponsor
- Pfizer
Aggression
Risperidone Augmentation for Treatment-Resistant Aggression in ADHD
Primary objectives: 1. To assess the short-term efficacy of risperidone augmentation for treatment-resistant aggression in children with ADHD. 2.
- Trial name
- NCT00297739
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Armenteros, Jorge L., M.D., P.A.